Citigroup Says This Obesity Drugmaker's Stock Is Now a Buy

In other words, it's a different path to the same endpoint and with a similar outcome. A pre-clinical study suggested average weight loss of 15% when BGE-102 is used on its own, and up to 25% weight reduction when used in conjunction with semaglutide -- the generic name for the key component of Novo Nordisk's Wegovy.BGE-102 is distinctly different from Novo Nordisk's and Eli Lilly's top-selling weight-management drugs, however. All of their flagship weight-loss drugs are GLP-1 receptor agonists that make yo ...